Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524400 | NSE Symbol : | ISIN : INE806D01016 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
23-May-2025	30-May-2025	Accounts	Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. The Audited Financial Results of the Company for the quarter and year ended 31st March 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 32nd Annual General Meeting of the Company. 3. To consider the appointment of M/s Meenu Maheshwari & Associates Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2025-26. 4. To consider the re-appointment of Mr. Arvind Sapkal [DIN: 08607096] for the further term of Five years as an Independent Non-Executive Director of the Company. 5. To consider the re-appointment of Internal Auditors of the Company for the year 2025-26. 6. To take on record Disclosure of Interest of Directors. 7. Any other matter with permission of the Chair.
06-Feb-2025	13-Feb-2025	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 31st December 2024. 2. Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.13th February, 2025 have 1. Approved the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2024. and the Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. Approval of the Unaudited Financial Results of the Company for the quarter ended 31st December, 2024, the limited review report issued by statutory auditor of the company attached herewith. (As Per BSE Announcement Dated on 13.02.2025)
06-Nov-2024	12-Nov-2024	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve 1.To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2024. 2.Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 12th November, 2024 have 1. Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2024. The Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. 2. Acceptance of the Resignation received from Mr. Govind Madanlal Gupta [DIN: 00052690], non-executive independent Director of the Company, due to his pre-occupation and other professional commitments, with effect from close of business hours on 12th November, 2024. Read less.. (As Per BSE Announcement Dated on: 12/11/2024)
07-Aug-2024	13-Aug-2024	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2024. 2. Any other matter with permission of the Chair. 1. Board of Directors of our company approved the appointment of Ms. Dhwani Solanki (DIN: 10299290) as as Additional director in the category of non executive independent director for 5 years, subject to the approval of shareholders of the Company. 2. Acceptance of resignation received from Mr. Niranjan Agrawal (DIN: 06503361) as non executive independent director, due to personal reasons with the effect from close of business hours on 13th August, 2024. (As Per Bse Announcement Dated on 13.08.2024)
23-May-2024	30-May-2024	Accounts	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve the following business: 1. To consider approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations 2015. 2.To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 31st Annual General Meeting of the Company. 3.To consider the re-appointment of M/s Meenu Maheshwari & Associates Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2024-25. 4.To consider the re-appointment of Internal Auditors of the Company for the year 2024-25. 5.To take on record Disclosure of Interest of Directors. 6.Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its Board Meeting held on Thursday, 30th May, 2024, inter-alia, considered the following matters: 1. Considered and approved the Audited Financial Results of the Company for the quarter and year ended 31st March, 2024. 2.Considered and approved the Directors' Report with the Annexure, Corporate Governance report, Management Discussion and Analysis Report and Notice for convening the 31th Annual General Meeting of the Company. 3. Considered and approved the re-appointment of M/s Meenu Maheshwari & Associates, Practicing Company Secretaries, as the Secretarial Auditor of the Company for the year 2024-25. 4. Considered and approved the re-appointment of Internal Auditors of the Company for the year 2024-25. 5. Taken on record the Disclosure of Interest of Directors of the Company for the year 2024-25. Read less.. Outcome of Board Meeting held on 30th May, 2024 (As Per BSE Announcement Dated on 30.05.2024)
02-Feb-2024	13-Feb-2024	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the following business: 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 31st December 2023. 2. Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.13th February, 2024 have 1. Approved the Unaudited Financial Results with Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended 31st December, 2023. (As Per BSE Announcement dated on 13.02.2024)
31-Oct-2023	08-Nov-2023	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve the following business: 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2023. 2. Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.8th November, 2023 have 1. Approved the Unaudited Financial Results with Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended 30th September, 2023. Approval of Unaudited Financial Results with Limited Review Report issued by statutory auditor of the Company for the quarter ended 30th September, 2023. (As per BSE Announcement Dated on 08/11/2023)
03-Aug-2023	12-Aug-2023	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve the following business: 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2023. 2. Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.12th August, 2023 have 1. Approved the Unaudited Financial Results with Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended 30th June, 2023. Approval of Unaudited Financial Results with the Limited Review report issued by the Statutory Auditor of the Company for the quarter ended 30th June, 2023. (As per BSE Announcement Dated on 12/08/2023)
23-May-2023	30-May-2023	Accounts	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve the following business: 1.To consider approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March 2023 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2.To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 30th Annual General Meeting of the Company. 3.To consider the re-appointment of M/s Meenu Maheshwari & Associates Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2023-24. 4.To consider the re-appointment of Internal Auditors of the Company for the year 2023-24. 5.To take on record Disclosure of Interest of Directors. 6.Any other matter with permission of the Chair. The Board of Directors of Ishita Drugs and Industries Limited, at its Board Meeting held on Tuesday, 30th May, 2023, inter-alia, considered the following matters: 1. Approved the Audited Financial Results of the Company for the quarter and year ended 31st March, 2023. 2. Approved the Directors' Report with the Annexure, Corporate Governance report, Management Discussion and Analysis Report and Notice for convening the 30th Annual General Meeting of the Company. 3. Approved the re-appointment of M/s Meenu Maheshwari & Associates, Practicing Company Secretaries, as the Secretarial Auditor of the Company for the year 2023-24. 4. Approved the re-appointment of Internal Auditors of the Company for the year 2023-24. 5. Taken on record the Disclosure of Interest of Directors of the Company for the year 2023-24. Approved the Audited Financial Results of the Company for the quarter and year ended 31st March, 2023 (As Per BSE Announcement dated on 30.05.2023)
07-Feb-2023	14-Feb-2023	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Notice is hereby given that pursuant to Regulation 29 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of the Company will be held on Tuesday 14th February 2023 to transact the following business: 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 31st December 2022. 2. Any other matter with permission of the Chair. Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.14th February, 2023 have Approved the Unaudited Financial Results of the Company along with the limited review report by Statutory Auditor for the quarter ended 31st December, 2022. (As Per BSE Announcement Dated on 14.02.2023)
07-Nov-2022	14-Nov-2022	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve Notice is hereby given that pursuant to Regulation 29 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of the Company will be held on Monday 14th November 2022 to transact the following business: 1.To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2022. 2.Any other matter with permission of the Chair. Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 14th November, 2022 have Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022. Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 14th November, 2022 have Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022. (As Per BSE Announcement Dated on 14.11.2022) Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 14th November, 2022, commenced at 2:00 p.m. and concluded at 2:40 p.m. have Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022. (As Per BSE Announcement Dated on 17.11.2022)
06-Aug-2022	13-Aug-2022	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2022 inter alia to consider and approve Notice is hereby given that pursuant to Regulation 29 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of the Company will be held on Saturday 13th August 2022 to transact the following business: 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2022. 2. Any other matter with permission of the Chair. Kindly take the above on your records. Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 13th August, 2022 have Approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2022. (As Per BSE Announcement Dated on 13/08/2022)
24-May-2022	30-May-2022	Accounts	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve 1.To consider the Audited Financial Results of the Company for the quarter and year ended 31st March 2022 2.To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 29th Annual General Meeting of the Company. 3. To consider increase in the Authorised Share Capital of the Company and consequent alteration in clause V (capital clause) of Memorandum of Association. 4.To consider the adoption of revised Articles of Association of the Company to align it with the regulations of Companies Act 2013. 5. To consider the re-appointment of M/s Meenu Maheshwari & Associates Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2022-23. 6.To take on record Disclosure of Interest of Directors. 7.Any other matter with permission of the Chair. Kindly take the above on your records. Approved the Audited Financial Results of the Company for the quarter and year ended 31st March, 2022. 1. Approved the Audited Financial Results of the Company . 2. Approved the increase in the Authorised Share Capital of the Company . 3. Approved the adoption of revised Articles of Association of the Company. 4. Approved the re-appointment of M/s Meenu Maheshwari & Associates, Practicing Company Secretaries, as the Secretarial Auditor of the Company. Please take the above details on your records. (As Per BSE Announcement Dated on 30/05/2022)
07-Feb-2022	14-Feb-2022	Quarterly Results	ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve Notice is hereby given that pursuant to Regulation 29 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of the Company will be held on Monday 14th February 2022 to transact the following businesses: 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended on 31st December 2021. 2. Any other matter with permission of the Chair. Kindly take the above on your records. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 14th February, 2022 have approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter ended on 31st December, 2021. (As Per BSE Announcement Dated 14.02.2022)
27-Oct-2021	02-Nov-2021	Quarterly Results	Quarterly Results Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e 2nd November, 2021 have approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter and half- year ended on 30th September, 2021. (As Per BSE Announcement Dated 02.11.2021)

1 2

LOGIN HERE

Ishita Drugs & Industries Ltd

Board Meeting